Patents Assigned to Matrixx Initiatives, Inc.
-
Publication number: 20200330540Abstract: The present disclosure describes pharmaceutical compositions and methods for reducing duration, intensity, and/or bothersomeness of common colds in humans and for reducing severity or duration of common cold symptoms such as nasal congestion, runny nose, watery eyes, dry/scratchy throat and sneezing in humans exhibiting such symptoms. The compositions herein comprise extracts of at least one of Luffa Operculata (L. operculata), S. officinale (V. sabadilla), and Galphimia Glauca (G. glauca) in a pharmaceutically acceptable carrier, and in various embodiments, comprise a mixture of all three Luffa Operculata (L. operculata) 10% extract MT, S. officinale (V. sabadilla) 3× extract, and Galphimia Glauca (G. glauca) 10% extract MT in a pharmaceutically acceptable carrier.Type: ApplicationFiled: July 7, 2020Publication date: October 22, 2020Applicant: Matrixx Initiatives, Inc.Inventors: Timothy L. Clarot, Arlene M. Ascarate
-
Patent number: 10736931Abstract: The present disclosure describes pharmaceutical compositions and methods for reducing duration, intensity, and/or bothersomeness of common colds in humans and for reducing severity or duration of common cold symptoms such as nasal congestion, runny nose, watery eyes, dry/scratchy throat and sneezing in humans exhibiting such symptoms. The compositions herein comprise extracts of at least one of Luffa Operculata (L. operculata), S. officinale (V. sabadilla), and Galphimia Glauca (G. glauca) in a pharmaceutically acceptable carrier, and in various embodiments, comprise a mixture of all three Luffa Operculata (L. operculata) 10% extract MT, S. officinale (V. sabadilla) 3× extract, and Galphimia Glauca (G. glauca) 10% extract MT in a pharmaceutically acceptable carrier.Type: GrantFiled: December 21, 2016Date of Patent: August 11, 2020Assignee: MATRIXX INITIATIVES, INC.Inventors: Timothy L. Clarot, Arlene M. Ascarate
-
Publication number: 20200237657Abstract: The present disclosure describes pharmaceutical compositions and methods for cleansing the nose, clearing the nose, imparting a cooling sensation in the nose, moisturizing nasal passages, soothing a dry nose, and ameliorating dehydration of the anterior nasal mucosa in humans in need of relief thereof. The compositions herein comprise humectants such as Aloe barbadensis leaf gel, hyaluronic acid, and/or a hyaluronate salt in a buffered and thickened pharmaceutically acceptable carrier. In various aspects, methods for relief comprise nasally administering compositions comprising Aloe barbadensis leaf gel and sodium hyaluronate in a pharmaceutically acceptable carrier to a human in need of relief thereof.Type: ApplicationFiled: January 28, 2019Publication date: July 30, 2020Applicant: Matrixx Initiatives, Inc.Inventors: Timothy L. Clarot, Arlene M. Ascarate
-
Publication number: 20170100446Abstract: The present disclosure describes pharmaceutical compositions and methods for reducing duration, intensity, and/or bothersomeness of common colds in humans and for reducing severity or duration of common cold symptoms such as nasal congestion, runny nose, watery eyes, dry/scratchy throat and sneezing in humans exhibiting such symptoms. The compositions herein comprise extracts of at least one of Luffa Operculata (L. operculata), S. officinale (V. sabadilla), and Galphimia Glauca (G. glauca) in a pharmaceutically acceptable carrier, and in various embodiments, comprise a mixture of all three Luffa Operculata (L. operculata) 10% extract MT, S. officinale (V. sabadilla) 3× extract, and Galphimia Glauca (G. glauca) 10% extract MT in a pharmaceutically acceptable carrier.Type: ApplicationFiled: December 21, 2016Publication date: April 13, 2017Applicant: Matrixx Initiatives, Inc.Inventors: Timothy L. Clarot, Arlene M. Ascarate
-
Patent number: 9555069Abstract: The present disclosure describes pharmaceutical compositions and methods for reducing duration, intensity, and/or bothersomeness of common colds in humans and for reducing severity or duration of common cold symptoms such as nasal congestion, runny nose, watery eyes, dry/scratchy throat and sneezing in humans exhibiting such symptoms. The compositions herein comprise extracts of at least one of Luffa Operculata (L. operculata), S. officinale (V. sabadilla), and Galphimia Glauca (G. glauca) in a pharmaceutically acceptable carrier, and in various embodiments, comprise a mixture of all three Luffa Operculata (L. operculata) 10% extract MT, S. officinale (V. sabadilla) 3× extract, and Galphimia Glauca (G. glauca) 10% extract MT in a pharmaceutically acceptable carrier.Type: GrantFiled: April 29, 2015Date of Patent: January 31, 2017Assignee: MATRIXX INITIATIVES, INC.Inventors: Timothy L. Clarot, Arlene M. Ascarate
-
Publication number: 20150231191Abstract: The present disclosure describes pharmaceutical compositions and methods for reducing duration, intensity, and/or bothersomeness of common colds in humans and for reducing severity or duration of common cold symptoms such as nasal congestion, runny nose, watery eyes, dry/scratchy throat and sneezing in humans exhibiting such symptoms. The compositions herein comprise extracts of at least one of Luffa Operculata (L. operculata), S. officinale (V. sabadilla), and Galphimia Glauca (G. glauca) in a pharmaceutically acceptable carrier, and in various embodiments, comprise a mixture of all three Luffa Operculata (L. operculata) 10% extract MT, S. officinale (V. sabadilla) 3× extract, and Galphimia Glauca (G. glauca) 10% extract MT in a pharmaceutically acceptable carrier.Type: ApplicationFiled: April 29, 2015Publication date: August 20, 2015Applicant: Matrixx Initiatives, Inc.Inventors: Timothy L. Clarot, Arlene M. Ascarate
-
Patent number: 9034401Abstract: The present disclosure describes pharmaceutical compositions and methods for reducing duration, intensity, and/or bothersomeness of common colds in humans and for reducing severity or duration of common cold symptoms such as nasal congestion, runny nose, watery eyes, dry/scratchy throat and sneezing in humans exhibiting such symptoms. The compositions herein comprise extracts of at least one of Luffa Operculata (L. operculata), S. officinale (V. sabadilla), and Galphimia Glauca (G. glauca) in a pharmaceutically acceptable carrier, and in various embodiments, comprise a mixture of all three Luffa Operculata (L. operculata) 10% extract MT, S. officinale (V. sabadilla) 3× extract, and Galphimia Glauca (G. glauca) 10% extract MT in a pharmaceutically acceptable carrier.Type: GrantFiled: July 9, 2014Date of Patent: May 19, 2015Assignee: MATRIXX INITIATIVES, INC.Inventors: Timothy L. Clarot, Arlene M. Ascarate
-
Patent number: 7439269Abstract: An improved composition and method for moisturizing a nasal membrane are disclosed. The composition includes a viscous carrier and one or more moisturizing agents disposed with the carrier. The composition is applied to a portion of a nasal membrane using a spray, a swab applicator, or a similar application device.Type: GrantFiled: April 18, 2005Date of Patent: October 21, 2008Assignee: Matrixx Initiatives, Inc.Inventors: Tim Clarot, Charles Hensley